- Trials with a EudraCT protocol (12)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
12 result(s) found for: Intrauterine hypoxia.
Displaying page 1 of 1.
| EudraCT Number: 2016-003621-41 | Sponsor Protocol Number: DESIRED | Start Date*: 2016-12-05 |
| Sponsor Name:Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital | ||
| Full Title: Desferal administration to improve the impaired reaction to hypoxia in diabetes (DESIRED) A randomised, double-blind, placebo-controlled, cross-over study | ||
| Medical condition: The study will investigate the effect of deferoxamine on the impaired reaction to hypoxia in patients with diabetes mellitus type 1. | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: SE (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2012-001049-42 | Sponsor Protocol Number: | Start Date*: 2012-07-05 |
| Sponsor Name:Department of Oncology, Rigshospitalet | ||
| Full Title: MRI-perfusion and FLT- and FET-PET during bevacizumab monotherapy for patients with recurrent Glioblastoma Multiforme | ||
| Medical condition: Recurrent Glioblastoma multiforme | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DK (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2015-003063-12 | Sponsor Protocol Number: NEU-01-02-1A | Start Date*: 2016-09-14 | ||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Neurophyxia B.V. | ||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: TIBC study: A multiple-centre Phase 2 trial comparing the efficacy of 2-Iminobiotin (2-IB) treatment to standard care in neonates with gestational age of ≥36 weeks with moderate to severe perinatal... | ||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Perinatal asphyxia | ||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Preterm newborn infants, Newborns, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: Outside EU/EEA | ||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2010-021621-12 | Sponsor Protocol Number: NAI114373 | Start Date*: 2010-12-01 | |||||||||||
| Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
| Full Title: NAI114373: A Phase III international, randomized, double-blind, double-dummy study to evaluate the efficacy and safety of 300 mg or 600 mg of intravenous zanamivir twice daily compared to 75 mg of ... | |||||||||||||
| Medical condition: hospitalised adults and adolescents with influenza | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: SK (Completed) DE (Completed) FR (Completed) GB (Completed) HU (Completed) NL (Completed) CZ (Completed) NO (Completed) DK (Completed) GR (Completed) BE (Completed) PL (Completed) ES (Completed) Outside EU/EEA | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-001654-15 | Sponsor Protocol Number: NL53018.015.15 | Start Date*: 2015-10-15 |
| Sponsor Name:Máxima Medisch Centrum | ||
| Full Title: Intrauterine resuscitation during term labor by maternal hyperoxygenation. | ||
| Medical condition: Fetal distress during the second stage of labor. | ||
| Disease: | ||
| Population Age: Adults | Gender: Female | |
| Trial protocol: NL (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2014-003138-18 | Sponsor Protocol Number: UCC-Strider | Start Date*: Information not available in EudraCT | |||||||||||
| Sponsor Name:University College Cork | |||||||||||||
| Full Title: STRIDER Ireland: A Randomised Controlled Trial of Sildenafil Therapy In Dismal Prognosis Early‐Onset Intrauterine Growth Restriction | |||||||||||||
| Medical condition: Severe early - onset Intrauterine Growth Restriction (IUGR), (also referred to as Fetal growth restriction) diagnosed between 22+0 and 29+6 gestational age. IUGR is defined as an estimated fetal we... | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults | Gender: Female | ||||||||||||
| Trial protocol: IE (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2006-005530-21 | Sponsor Protocol Number: AGO/2006/010 | Start Date*: 2007-01-12 | |||||||||||
| Sponsor Name:University Hospital Gent | |||||||||||||
| Full Title: Comparison of dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) with gadofosveset trisodium (Vasovist, Schering, Berlin, Germany) to gadopentetate dimeglumine (GD-DTPA, Magnevist, Sche... | |||||||||||||
| Medical condition: Metastatic colorectal cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2016-002512-40 | Sponsor Protocol Number: 201023 | Start Date*: 2016-12-05 | |||||||||||
| Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
| Full Title: A Phase II, global, randomized study to evaluate the efficacy and safety of Danirixin (GSK1325756) co-administered with a standard-of-care antiviral (oseltamivir), in the treatment of adults hospit... | |||||||||||||
| Medical condition: Hospitalized influenza | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SE (Completed) ES (Completed) NL (Prematurely Ended) FR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2012-003507-35 | Sponsor Protocol Number: AV-951-12-204 | Start Date*: 2013-05-20 | ||||||||||||||||
| Sponsor Name:AVEO Pharmaceuticals, Inc. | ||||||||||||||||||
| Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled, 2-Arm, Multi-Center Study Comparing Tivozanib Hydrochloride In Combination With Paclitaxel Versus Placebo In Combination With Paclitaxel in t... | ||||||||||||||||||
| Medical condition: Locally recurrent and/or metastatic triple negative breast cancer | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
| Trial protocol: IT (Prematurely Ended) ES (Prematurely Ended) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2021-003788-82 | Sponsor Protocol Number: SA2115 | Start Date*: 2022-02-15 | ||||||||||||||||
| Sponsor Name:Department of Oncology, Herlev & Gentofte Hospital | ||||||||||||||||||
| Full Title: An open label phase 2 study on propranolol and pembrolizumab in advanced Angiosarcoma and Undifferentiated Pleomorphic Sarcoma – a Scandinavian Sarcoma Group collaboration | ||||||||||||||||||
| Medical condition: Advanced Angiosarcoma and Undifferentiated Pleomorphic Sarcoma | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults | Gender: Male, Female | |||||||||||||||||
| Trial protocol: DK (Trial now transitioned) NO (Trial now transitioned) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2020-003629-45 | Sponsor Protocol Number: IOV-LUN-202 | Start Date*: 2021-05-05 | |||||||||||
| Sponsor Name:Iovance Biotherapeutics, Inc. | |||||||||||||
| Full Title: A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN -145) in Patients with Metastatic Non-Small-Cell Lung Cancer | |||||||||||||
| Medical condition: Metastatic Non-Small-Cell Lung Cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Trial now transitioned) DE (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2011-003895-35 | Sponsor Protocol Number: D4280C00005 | Start Date*: 2012-04-11 | |||||||||||
| Sponsor Name:AstraZeneca AB | |||||||||||||
| Full Title: A Phase III, Randomized, Multicenter, Double Blind, Double-Dummy Parallel-Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam Plus Metronidazole V... | |||||||||||||
| Medical condition: Complicated Intra-Abdominal Infection (cIAI) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) BE (Completed) CZ (Completed) GR (Completed) ES (Completed) BG (Completed) IT (Completed) LT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.